RZLT
What one share of Rezolute holds
Pharmaceutical Preparations
Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”).
Rezolute’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.75 |
|---|---|
| Cash and investments | $1.12 |
| Book value | $1.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$28.68 | — | −$16.12 | — | $8.66 |
| 2018 | — | −$26.83 | $0.01 | −$12.68 | — | — |
| 2020 | — | −$3.54 | $0.00 | −$4.20 | — | $1.26 |
| 2021 | — | −$2.72 | — | −$2.66 | — | $3.12 |
| 2022 | — | −$2.32 | — | −$2.03 | — | $4.45 |
| 2023 | — | −$1.01 | $0.00 | −$0.87 | — | $3.15 |
| 2024 | — | −$1.33 | — | −$1.11 | — | $2.27 |
| 2025 | — | −$0.98 | — | −$0.91 | — | $1.86 |
| 2026 | — | −$0.75 | — | −$0.62 | — | $1.04 |